PL2607484T3 - Sposoby i środki do wydajnego pomijania eksonu 45 w pre-mRNA dystrofii mięśniowej Duchenne'a - Google Patents

Sposoby i środki do wydajnego pomijania eksonu 45 w pre-mRNA dystrofii mięśniowej Duchenne'a

Info

Publication number: PL2607484T3
Authority: PL; Poland
Prior art keywords: exon; mrna; methods; muscular dystrophy; duchenne muscular
Prior art date: 2008-10-27

Application number

PL13160338T

Other languages

English (en)

Inventor

Kimpe Josephus Johannes De

Gerardus Johannes Platenburg

Deutekom Judith Christina Theodora Van

Annemieke Aartsma-Rus

Ommen Garrit-Jan Boudewijn Van

Original Assignee

Biomarin Tech Bv

Academisch Ziekenhuis Leiden

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-27

Filing date

2009-01-13

Publication date

2016-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40873329&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2607484(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-27 Priority claimed from PCT/NL2008/050673 external-priority patent/WO2009054725A2/en

2009-01-13 Application filed by Biomarin Tech Bv, Academisch Ziekenhuis Leiden filed Critical Biomarin Tech Bv

2016-06-30 Publication of PL2607484T3 publication Critical patent/PL2607484T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL13160338T 2008-10-27 2009-01-13 Sposoby i środki do wydajnego pomijania eksonu 45 w pre-mRNA dystrofii mięśniowej Duchenne'a PL2607484T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/NL2008/050673 WO2009054725A2 (en)	2007-10-26	2008-10-27	Means and methods for counteracting muscle disorders
EP13160338.3A EP2607484B1 (en)	2008-10-27	2009-01-13	Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
EP09788160.1A EP2344637B2 (en)	2008-10-27	2009-01-13	Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna

Publications (1)

Publication Number	Publication Date
PL2607484T3 true PL2607484T3 (pl)	2016-06-30

Family

ID=40873329

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13160338T PL2607484T3 (pl)	2008-10-27	2009-01-13	Sposoby i środki do wydajnego pomijania eksonu 45 w pre-mRNA dystrofii mięśniowej Duchenne'a

Country Status (15)

Country	Link
EP (4)	EP2607484B1 (pl)
JP (2)	JP5786109B2 (pl)
AU (1)	AU2009310557B2 (pl)
CA (3)	CA2741629C (pl)
CY (1)	CY1116305T1 (pl)
DK (2)	DK2607484T3 (pl)
ES (2)	ES2562658T3 (pl)
HK (1)	HK1160169A1 (pl)
HR (1)	HRP20160078T1 (pl)
IL (2)	IL212509A (pl)
NZ (1)	NZ592498A (pl)
PL (1)	PL2607484T3 (pl)
PT (2)	PT2344637E (pl)
SI (1)	SI2607484T1 (pl)
WO (2)	WO2010050801A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE48960E1 (en)	2004-06-28	2022-03-08	The University Of Western Australia	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
ATE498685T1 (de)	2004-06-28	2011-03-15	Univ Western Australia	Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
DK2203173T3 (en)	2007-10-26	2016-02-29	Academisch Ziekenhuis Leiden	Materials and methods for prevention of muscle diseases
EP2119783A1 (en)	2008-05-14	2009-11-18	Prosensa Technologies B.V.	Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN102203253B (zh)	2008-10-24	2016-04-06	萨雷普塔治疗公司	用于dmd的多外显子跳跃组合物
US8802437B2 (en) *	2009-09-24	2014-08-12	Cellectis	Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
KR102113306B1 (ko)	2009-11-12	2020-05-21	더 유니버시티 오브 웨스턴 오스트레일리아	안티센스 분자 및 이를 이용한 질환 치료방법
TWI541024B (zh)	2010-09-01	2016-07-11	日本新藥股份有限公司	反義核酸
BR112013020273A2 (pt) *	2011-02-08	2016-10-18	Charlotte Mecklenburg Hospital	oligonucleotídeos antissenso
RU2619184C2 (ru) *	2011-12-28	2017-05-12	Ниппон Синяку Ко., Лтд.	Антисмысловые нуклеиновые кислоты
CN104203289B (zh)	2012-01-27	2020-11-03	比奥马林技术公司	用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP3608407A1 (en) *	2012-07-03	2020-02-12	BioMarin Technologies B.V.	Oligonucleotide for the treatment of muscular dystrophy patients
EA035882B1 (ru)	2013-03-14	2020-08-27	Сарепта Терапьютикс, Инк.	Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
WO2014144978A2 (en)	2013-03-15	2014-09-18	Sarepta Therapeutics, Inc.	Improved compositions for treating muscular dystrophy
TWI736514B (zh) *	2013-09-05	2021-08-21	美商薩羅塔治療公司	酸性α葡萄糖苷酶之反義股誘導之外顯子２包含
JP6519842B2 (ja) *	2013-10-04	2019-05-29	国立大学法人神戸大学	福山型筋ジストロフィー治療用アンチセンス核酸
MY193708A (en) *	2014-03-12	2022-10-26	Nippon Shinyaku Co Ltd	Antisense nucleic acids
HRP20220379T1 (hr) *	2014-06-10	2022-05-27	Erasmus University Medical Center Rotterdam	Antisense oligonukleotidi korisni u liječenju pompeove bolesti
PT3351633T (pt) *	2015-09-15	2020-07-29	Nippon Shinyaku Co Ltd	Ácido nucleico antissentido
PE20181353A1 (es)	2015-10-09	2018-08-22	Wave Life Sciences Ltd	Composiciones oligonucleotidicas y sus metodos
US11339392B2 (en)	2016-03-02	2022-05-24	The Board Of Trustees Of The Leland Stanford Junior University	Pan-genotypic agents against influenza virus and methods of using the same
LT3800257T (lt) *	2016-03-02	2024-07-25	The Board Of Trustees Of The Leland Stanford Junior University	Pangenotipiniai agentai nuo gripo virusų ir jų naudojimo būdai
MA45328A (fr)	2016-04-01	2019-02-06	Avidity Biosciences Llc	Compositions acide nucléique-polypeptide et utilisations de celles-ci
US11060089B2 (en)	2016-04-18	2021-07-13	Sarepta Therapeutics, Inc.	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
MA45290A (fr) *	2016-05-04	2019-03-13	Wave Life Sciences Ltd	Procédés et compositions d'agents biologiquement actifs
KR20190024977A (ko)	2016-06-30	2019-03-08	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머
MX2018016253A (es) *	2016-07-05	2019-09-09	Biomarin Tech Bv	Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
PL3554554T3 (pl)	2016-12-19	2022-12-19	Sarepta Therapeutics, Inc.	Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
CA3047010A1 (en)	2016-12-19	2018-06-28	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
KR20230110811A (ko)	2016-12-19	2023-07-25	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
SG10202107429WA (en)	2017-01-06	2021-08-30	Avidity Biosciences Inc	Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB201711809D0 (en) *	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20210145852A1 (en)	2017-09-28	2021-05-20	Sarepta Therapeutics, Inc.	Combination Therapies for Treating Muscular Dystrophy
SG11202003126VA (en)	2017-10-04	2020-05-28	Avidity Biosciences Inc	Nucleic acid-polypeptide compositions and uses thereof
KR102443358B1 (ko)	2017-12-06	2022-09-14	어비디티 바이오사이언시스 인크.	근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
WO2019241385A2 (en) *	2018-06-13	2019-12-19	Sarepta Therapeutics, Inc.	Exon skipping oligomers for muscular dystropy
JP2021533200A (ja)	2018-08-02	2021-12-02	ダインセラピューティクス, インコーポレーテッドDyne Therapeutics, Inc.	顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100934PA (en)	2018-08-02	2021-02-25	Dyne Therapeutics Inc	Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020118246A1 (en) *	2018-12-06	2020-06-11	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP3980436A4 (en)	2019-06-06	2023-12-20	Avidity Biosciences, Inc.	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
JP2022535911A (ja)	2019-06-06	2022-08-10	アビディティーバイオサイエンシーズ，インク．	Ｕｎａアミダイトおよびその使用
EP4079329A4 (en) *	2019-12-19	2024-04-17	Nippon Shinyaku Co., Ltd.	ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
CN118109468A (zh)	2019-12-26	2024-05-31	日本新药株式会社	诱导外显子50的跳读的反义核酸
IL295967A (en)	2020-02-28	2022-10-01	Nippon Shinyaku Co Ltd	Antisense nucleic acids for splicing on exon 51
US11555190B2 (en)	2020-03-19	2023-01-17	Avidity Biosciences, Inc.	Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023127918A1 (ja)	2021-12-27	2023-07-06	日本新薬株式会社	オリゴ核酸化合物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003511362A (ja)	1999-10-04	2003-03-25	ユニバーシティーオブメディシンアンドデンティストリーオブニュージャージー	新規カルバメートおよび尿素類
US6727355B2 (en) *	2000-08-25	2004-04-27	Jcr Pharmaceuticals Co., Ltd.	Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) *	2000-08-25	2011-12-14	雅文松尾	デュシェンヌ型筋ジストロフィー治療剤
WO2004083432A1 (en) *	2003-03-21	2004-09-30	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ATE498685T1 (de) *	2004-06-28	2011-03-15	Univ Western Australia	Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
WO2006112705A2 (en) *	2005-04-22	2006-10-26	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
EP1857548A1 (en) *	2006-05-19	2007-11-21	Academisch Ziekenhuis Leiden	Means and method for inducing exon-skipping
DK2203173T3 (en)	2007-10-26	2016-02-29	Academisch Ziekenhuis Leiden	Materials and methods for prevention of muscle diseases
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
CN102203253B (zh) *	2008-10-24	2016-04-06	萨雷普塔治疗公司	用于dmd的多外显子跳跃组合物
US9607308B2 (en)	2011-06-29	2017-03-28	American Express Travel Related Services Company, Inc.	Spend based digital ad targeting and measurement

2009
- 2009-01-13 EP EP13160338.3A patent/EP2607484B1/en not_active Revoked
- 2009-01-13 AU AU2009310557A patent/AU2009310557B2/en active Active
- 2009-01-13 JP JP2011533126A patent/JP5786109B2/ja active Active
- 2009-01-13 CA CA2741629A patent/CA2741629C/en active Active
- 2009-01-13 EP EP09788160.1A patent/EP2344637B2/en active Active
- 2009-01-13 PT PT09788160T patent/PT2344637E/pt unknown
- 2009-01-13 ES ES13160338.3T patent/ES2562658T3/es active Active
- 2009-01-13 WO PCT/NL2009/050006 patent/WO2010050801A1/en active Application Filing
- 2009-01-13 DK DK13160338.3T patent/DK2607484T3/en active
- 2009-01-13 SI SI200931381A patent/SI2607484T1/sl unknown
- 2009-01-13 ES ES09788160.1T patent/ES2532634T5/es active Active
- 2009-01-13 PL PL13160338T patent/PL2607484T3/pl unknown
- 2009-01-13 PT PT131603383T patent/PT2607484E/pt unknown
- 2009-01-13 DK DK09788160.1T patent/DK2344637T4/en active
- 2009-03-11 EP EP18180952.6A patent/EP3400948B1/en active Active
- 2009-03-11 EP EP09788170.0A patent/EP2349287B1/en active Active
- 2009-03-11 CA CA3017539A patent/CA3017539A1/en active Pending
- 2009-03-11 JP JP2011533127A patent/JP5905260B2/ja active Active
- 2009-03-11 WO PCT/NL2009/050113 patent/WO2010050802A2/en active Application Filing
- 2009-03-11 NZ NZ592498A patent/NZ592498A/en unknown
- 2009-03-11 CA CA2741793A patent/CA2741793C/en active Active
2011
- 2011-04-27 IL IL212509A patent/IL212509A/en active IP Right Grant
- 2011-04-27 IL IL212508A patent/IL212508A/en active IP Right Grant
2012
- 2012-01-16 HK HK12100495.6A patent/HK1160169A1/xx active IP Right Maintenance
2015
- 2015-03-04 CY CY20151100228T patent/CY1116305T1/el unknown
2016
- 2016-01-25 HR HRP20160078TT patent/HRP20160078T1/hr unknown

Also Published As

Publication number	Publication date
PT2344637E (pt)	2015-03-23
SI2607484T1 (sl)	2016-11-30
CA3017539A1 (en)	2010-05-06
EP2349287B1 (en)	2018-08-15
EP2349287A2 (en)	2011-08-03
IL212508A0 (en)	2011-06-30
AU2009310558A1 (en)	2010-05-06
IL212508A (en)	2013-11-28
HK1160169A1 (en)	2012-08-10
JP5905260B2 (ja)	2016-04-20
JP5786109B2 (ja)	2015-09-30
ES2532634T3 (es)	2015-03-30
DK2607484T3 (en)	2016-03-07
EP2344637A1 (en)	2011-07-20
IL212509A (en)	2016-04-21
AU2009310558A8 (en)	2015-01-22
AU2009310557A1 (en)	2010-05-06
CA2741793A1 (en)	2010-05-06
WO2010050801A1 (en)	2010-05-06
WO2010050802A2 (en)	2010-05-06
CY1116305T1 (el)	2017-02-08
NZ592498A (en)	2012-05-25
AU2009310558B2 (en)	2014-09-04
CA2741629A1 (en)	2010-05-06
EP2607484A1 (en)	2013-06-26
PT2607484E (pt)	2016-03-09
ES2532634T5 (es)	2018-04-30
WO2010050802A3 (en)	2010-08-12
CA2741793C (en)	2018-10-30
DK2344637T4 (en)	2018-04-23
AU2009310557A8 (en)	2011-09-29
EP2344637B1 (en)	2014-12-24
HRP20160078T1 (hr)	2016-04-08
EP3400948B1 (en)	2022-11-02
JP2012506697A (ja)	2012-03-22
DK2344637T3 (en)	2015-02-02
IL212509A0 (en)	2011-06-30
EP2607484B1 (en)	2016-01-06
CA2741629C (en)	2022-07-05
ES2562658T3 (es)	2016-03-07
EP3400948A1 (en)	2018-11-14
EP2344637B2 (en)	2018-02-28
AU2009310557B2 (en)	2014-09-11
JP2012506698A (ja)	2012-03-22

Publication	Publication Date	Title
IL212508A0 (en)	2011-06-30	Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
IL282772B1 (en)	2023-03-01	A method for efficient exon skipping (44) in Duchenne muscular dystrophy and related measures
HK1185098A1 (zh)	2014-02-07	高效跳過裘馨氏肌肉營養不良症前體外顯子的方法和工具
IL278833A (en)	2021-01-31	Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
GB0715938D0 (en)	2007-09-26	Method of treatment of duchenne muscular dystrophy
EP2296805A4 (en)	2011-12-28	PROCESS AND APPARATUS FOR THE MANUFACTURE OF TITANIUM ALUMINUM ALLOYS
ZA201100651B (en)	2012-02-29	Method for dispersing and separating nanotubes
EP2247950A4 (en)	2011-04-13	METHODS AND COMPOSITIONS FOR DETECTING MICROORGANISMS
GB0818401D0 (en)	2008-11-12	Fastener feed method and apparatus
HK1160721A1 (en)	2012-08-17	Methods and apparatuses for plant aeration
HK1132307A1 (en)	2010-02-19	Electroplating device and method for electroplating
EP2190986A4 (en)	2012-01-11	HYBRIDIZATION METHOD AND APPARATUS
EP2340315A4 (en)	2012-04-25	COMPOSITIONS AND METHODS FOR DETECTION OF JAK2 NUCLEIC ACID MUTATIONS
IL209324A0 (en)	2011-01-31	Aliskiren monofumarate and processes for preparation thereof
EP2495040A4 (en)	2015-12-16	AGITATOR DEVICE AND STIRRER HOOKS FOR THE SAME
EP2319247A4 (en)	2012-05-09	METHODS AND APPARATUS FOR PROCESSING AND DISPLAYING IMAGE
GB0817991D0 (en)	2008-11-05	Fluorescence based detection methods and apparatus
EP2330950A4 (en)	2012-10-24	LOCKABLE LOCHWORK MOUNTING AND METHOD
TWI368845B (en)	2012-07-21	Multimedia palying method and apparatus thereof
TWI371971B (en)	2012-09-01	De-interlacing method and apparatus
TWI347126B (en)	2011-08-11	Dynamic de-interlacing method and apparatus
GB0713944D0 (en)	2007-08-29	In-Vessel composting apparatus and method